- Genmab to acquire ProfoundBio for USD 1.8 billion in cash
- Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms
- Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRĪ±) in development for the treatment of ovarian cancer and other solid tumors
- Genmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT
Genmab will hold a conference call to discuss the transaction today, April 3 at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT. To join the call please use the following registration link: https://register.vevent.com/register/BI9da0549848d848cdaa4b6cd96079bafd. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN. To listen to a live webcast of the call please use the following link: https://edge.media-server.com/mmc/p/fxctprh2. An archive of the webcast and relevant slides will be available at https://www.Genmab.com/investors/.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.